StreetInsider.com News Articles

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

DENVER, June 16, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – Multiple clinical-stage companies are delivering meaningful regulatory, clinical, and corporate milestones. From brain cancer drug development and cell therapy expansion to neurodegenerative disease programs and cardiovascular breakthroughs, investors were presented with a wave of catalysts that are driving enthusiasm across several emerging healthcare names. Traders appeared particularly focused on companies advancing toward late-stage clinical development, securing new regulatory clearances, or gaining broader visibility through public market events.

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Biotech Bulls Stampede as Clinical Wins and Milestones Fuel Momentum

Tue, 16 Jun 2026 10:18:28 -0400

Download the 24/7 Market News App here https://app.247mnn.com/ or on the App Store

Among

Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX)

Tue, 16 Jun 2026 09:00:29 -0400

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $52.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).

The analyst comments "Today's data release of positive Ph2 data showed EDG-7500 is efficacious and well-tolerated in both oHCM and nHCM patients & we continue to view this drug as differentiated on LVEF profile. The stock is down pre-market today despite data that we believe indicate an active drug with a differentiated safety profile that could make it best-in-class. We believe investors may be concerned about enrollment timelines, and the potential necessity for Edgewise to run a head-to-head trial with approved CMIs, and

Truist Securities Reiterates Buy Rating on Edgewise Therapeutics (EWTX)

Tue, 16 Jun 2026 09:00:29 -0400

Truist Securities analyst Srikripa Devarakonda reiterated a Buy rating and $52.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).

Leerink: 'CIRRUS Part D data continue to look supportive of EDG-7500’s potential'

Tue, 16 Jun 2026 08:55:57 -0400

Leerink analyst Joseph Schwartz reiterated an Outperform rating and $50.00 price target on Edgewise Therapeutics (NASDAQ: EWTX)

The analyst comments "CIRRUS Part D data continue to look supportive of EDG-7500’s potential as a differentiated treatment for both obstructive (oHCM) and non-obstructive hypertrophic cardiomyopathy (nHCM), with durable improvements across hemodynamics, biomarkers, diastolic function, and patientreported/functional outcomes at 12 weeks. Where initial comparisons can be made, the Part D data look consistent to improved versus the prior readout, including sustained oHCM KCCQ benefit, a stronger nHCM NT-proBNP signal, and lower observed atrial fibrillation (AF) incidence with dose optimization. Importantly, the larger and longer

Leerink: 'CIRRUS Part D data continue to look supportive of EDG-7500’s potential'

Tue, 16 Jun 2026 08:55:57 -0400

Leerink analyst Joseph Schwartz reiterated an Outperform rating and $50.00 price target on Edgewise Therapeutics (NASDAQ: EWTX)

SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall

Tue, 16 Jun 2026 08:18:25 -0400

Investing.com - U.S. stock futures were little changed on Tuesday, while oil prices extended recent losses, as investors awaited further details on a preliminary peace agreement between the United States and Iran.

By 08:13 ET (12:13 GMT), the Dow futures contract was mostly flat, S&P 500 futures had slipped by 5 points, or 0.1%, and Nasdaq 100 futures had edged up 0.23%.

Here are some of the biggest premarket U.S. stock movers today:

Artificial intelligence and technology shares remained in focus, while merger activity and healthcare names also generated notable premarket moves.

SpaceX (NASDAQ:SPCX) rose more than 8% in premarket trading, extending

SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall

Tue, 16 Jun 2026 08:18:25 -0400

By 08:13 ET (12:13 GMT), the Dow futures contract was mostly flat, S&P 500 futures had slipped by 5 points, or 0.1%, and Nasdaq 100 futures had edged up 0.23%.

Here are some of the biggest premarket U.S. stock movers today:

Artificial intelligence and technology shares remained in focus, while merger activity and healthcare names also generated notable premarket moves.

SpaceX (NASDAQ:SPCX) rose more than 8% in premarket trading, extending

SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall

Tue, 16 Jun 2026 08:18:25 -0400

By 08:13 ET (12:13 GMT), the Dow futures contract was mostly flat, S&P 500 futures had slipped by 5 points, or 0.1%, and Nasdaq 100 futures had edged up 0.23%.

Here are some of the biggest premarket U.S. stock movers today:

Artificial intelligence and technology shares remained in focus, while merger activity and healthcare names also generated notable premarket moves.

SpaceX (NASDAQ:SPCX) rose more than 8% in premarket trading, extending

SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall

Tue, 16 Jun 2026 08:18:25 -0400

By 08:13 ET (12:13 GMT), the Dow futures contract was mostly flat, S&P 500 futures had slipped by 5 points, or 0.1%, and Nasdaq 100 futures had edged up 0.23%.

Here are some of the biggest premarket U.S. stock movers today:

Artificial intelligence and technology shares remained in focus, while merger activity and healthcare names also generated notable premarket moves.

SpaceX (NASDAQ:SPCX) rose more than 8% in premarket trading, extending

SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall

Tue, 16 Jun 2026 08:18:25 -0400

By 08:13 ET (12:13 GMT), the Dow futures contract was mostly flat, S&P 500 futures had slipped by 5 points, or 0.1%, and Nasdaq 100 futures had edged up 0.23%.

Here are some of the biggest premarket U.S. stock movers today:

Artificial intelligence and technology shares remained in focus, while merger activity and healthcare names also generated notable premarket moves.

SpaceX (NASDAQ:SPCX) rose more than 8% in premarket trading, extending